Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 19,300 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $9.04 per share, with a total value of $174,472.00. Following the transaction, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $18,191,888. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on OPK shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday. They now have a $10.50 price target on the stock, down previously from $11.00. Finally, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $12.00.

Shares of Opko Health (NYSE:OPK) traded down 0.22% on Friday, hitting $9.09. The stock had a trading volume of 1,530,454 shares. Opko Health has a one year low of $7.32 and a one year high of $12.95. The stock has a 50-day moving average of $8.90 and a 200-day moving average of $8.79. The company’s market cap is $3.901 billion.

Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 11th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts predict that Opko Health will post $-0.33 earnings per share for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Receive News & Ratings for Opko Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.